A detailed history of Primecap Management CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Primecap Management CO holds 4,974,289 shares of BGNE stock, worth $966 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares
4,974,289
Previous 4,986,289 0.24%
Holding current value
$966 Million
Previous $711 Million 56.98%
% of portfolio
0.84%
Previous 0.52%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$143.93 - $224.51 $1.73 Million - $2.69 Million
-12,000 Reduced 0.24%
4,974,289 $1.12 Billion
Q2 2024

Aug 09, 2024

SELL
$129.52 - $174.32 $2.01 Million - $2.71 Million
-15,550 Reduced 0.31%
4,986,289 $711 Million
Q1 2024

May 13, 2024

BUY
$141.8 - $181.47 $1.87 Million - $2.4 Million
13,200 Added 0.26%
5,001,839 $782 Million
Q4 2023

Feb 09, 2024

SELL
$158.67 - $201.58 $3.19 Million - $4.05 Million
-20,100 Reduced 0.4%
4,988,639 $900 Million
Q3 2023

Nov 13, 2023

SELL
$179.87 - $225.13 $1.06 Million - $1.33 Million
-5,910 Reduced 0.12%
5,008,739 $901 Million
Q2 2023

Aug 11, 2023

SELL
$178.3 - $266.78 $5.58 Million - $8.34 Million
-31,275 Reduced 0.62%
5,014,649 $894 Million
Q1 2023

May 15, 2023

SELL
$215.53 - $274.5 $480,631 - $612,135
-2,230 Reduced 0.04%
5,045,924 $1.09 Billion
Q4 2022

Feb 13, 2023

BUY
$125.51 - $229.3 $39.3 Million - $71.8 Million
313,175 Added 6.61%
5,048,154 $1.11 Billion
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $92.7 Million - $142 Million
703,530 Added 17.45%
4,734,979 $638 Million
Q2 2022

Aug 11, 2022

BUY
$121.11 - $216.05 $39.1 Million - $69.7 Million
322,645 Added 8.7%
4,031,449 $652 Million
Q1 2022

May 11, 2022

SELL
$146.52 - $269.56 $1.28 Million - $2.35 Million
-8,703 Reduced 0.23%
3,708,804 $699 Million
Q4 2021

Feb 11, 2022

SELL
$248.56 - $389.34 $23.3 Million - $36.5 Million
-93,840 Reduced 2.46%
3,717,507 $1.01 Billion
Q3 2021

Nov 12, 2021

SELL
$249.6 - $403.14 $11.6 Million - $18.8 Million
-46,613 Reduced 1.21%
3,811,347 $1.38 Billion
Q2 2021

Aug 10, 2021

SELL
$292.75 - $367.01 $9.04 Million - $11.3 Million
-30,879 Reduced 0.79%
3,857,960 $1.32 Billion
Q1 2021

May 14, 2021

BUY
$260.64 - $382.12 $136 Million - $200 Million
522,112 Added 15.51%
3,888,839 $1.35 Billion
Q4 2020

Feb 08, 2021

SELL
$221.31 - $316.61 $1.23 Million - $1.76 Million
-5,560 Reduced 0.16%
3,366,727 $870 Million
Q3 2020

Nov 13, 2020

BUY
$189.18 - $286.44 $306 Million - $463 Million
1,616,090 Added 92.02%
3,372,287 $966 Million
Q2 2020

Aug 13, 2020

BUY
$123.9 - $195.41 $6.96 Million - $11 Million
56,176 Added 3.3%
1,756,197 $331 Million
Q1 2020

May 14, 2020

BUY
$121.84 - $173.19 $85.5 Million - $121 Million
701,444 Added 70.24%
1,700,021 $209 Million
Q4 2019

Feb 14, 2020

BUY
$115.78 - $208.34 $1.78 Million - $3.2 Million
15,347 Added 1.56%
998,577 $166 Million
Q3 2019

Nov 13, 2019

BUY
$120.61 - $148.29 $6.56 Million - $8.07 Million
54,391 Added 5.86%
983,230 $120 Million
Q2 2019

Aug 14, 2019

BUY
$113.99 - $146.86 $957,516 - $1.23 Million
8,400 Added 0.91%
928,839 $115 Million
Q1 2019

May 14, 2019

SELL
$122.82 - $151.83 $135,102 - $167,013
-1,100 Reduced 0.12%
920,439 $121 Million
Q4 2018

Feb 12, 2019

BUY
$107.01 - $175.15 $4.92 Million - $8.06 Million
46,000 Added 5.25%
921,539 $129 Million
Q3 2018

Nov 13, 2018

BUY
$152.62 - $189.66 $2.78 Million - $3.45 Million
18,206 Added 2.12%
875,539 $151 Million
Q2 2018

Aug 13, 2018

SELL
$152.5 - $216.77 $25,315 - $35,983
-166 Reduced 0.02%
857,333 $132 Million
Q1 2018

May 14, 2018

BUY
$97.41 - $177.22 $53.6 Million - $97.6 Million
550,479 Added 179.3%
857,499 $144 Million
Q4 2017

Feb 13, 2018

BUY
$79.6 - $114.73 $1.2 Million - $1.72 Million
15,015 Added 5.14%
307,020 $30 Million
Q3 2017

Nov 13, 2017

BUY
$66.19 - $103.46 $19.3 Million - $30.2 Million
292,005
292,005 $30.2 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.1B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.